Compare Enbridge Inc (ENB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs TG Therapeutics Inc — how do they compare? Enbridge Inc trades at $46.6 (market cap $103.38B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Enbridge Inc is far larger — about 12.7× TG Therapeutics Inc's market cap, and Enbridge Inc pays a 6.02% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and TG Therapeutics Inc for 16 Days on average.
| ENB | TGTX | |
|---|---|---|
Market Cap | $103.38B | $8.16B |
Volume | 3,684,305 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $58.04 | $59.06 |
52-Week Low | $45.23 | $26.94 |
Typical Hold Time | 91 Days | 16 Days |
Enterprise Value | $185.39B | $8.37B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $46.54, up 1.42% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.19B in 2025, and the dividend yield is attractive at approximately 6% based on the recent $0.97 payout. Analyst consensus is mixed with a $61.63 price target, indicating potential upside from current levels.
The outlook for ENB is supported by stable cash flows and a secured project backlog, but risks include high debt levels and sensitivity to interest rates. Investment opportunity lies in the dividend income and valuation discount to analyst targets, though investors face headwinds from energy market volatility and rising leverage.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
